Christopher O’Donnell
Company: Novartis Institutes of Biomedical Research
Job title: Global Head, Cardiovascular & Metabolism Translational Medicine
Seminars:
Translating Biomarker & Quality of Life Evaluation into Precision Medicine Approaches in HFpEF 1:45 pm
Describe risk factors and disease endotypes in evaluation for HFpEF clinical trials Define the state of proteomic/genomic, digital and cardiac imaging in precision medicine evaluation of HFpEF symptoms and disease progression Discuss the evolving landscape of HFpEF clinical trials and opportunities for precision medicineRead more
day: Day Two
Moderated Discussion – Outlining Methods to Improve the Quality of Life for HFpEF Patients 2:15 pm
What has been observed in previous trials with respect to mortality rates and what have interim analyses shown? What steps have been taken to improve this definition for HFpEF patient? How does changing the definition for quality of life subsequently alter the drug development industry?Read more
day: Day Two
Moderated Discussion – Consideration of Gene Therapy Effectiveness Resulting from Insights into Genetic Predisposition 5:45 pm
day: Day One
Panel Discussion – Could Imaging be Taken Further? Thinking Unconventionally About Diagnosis 3:30 pm
day: Day One